Surging cancer prevalence, expanding AI-powered diagnostics, and major healthcare digitalization initiatives accelerate the global AI in oncology market growth at a CAGR of 26.23% through 2032.
Austin, Nov. 14, 2025 (GLOBE NEWSWIRE) — AI in Oncology Market Size and Growth Analysis:
According to SNS Insider, the global AI in Oncology Market was valued at USD 4.22 billion in 2024 and is expected to reach USD 27.17 billion by 2032, growing at a CAGR of 26.23% during 2025–2032. The industry is undergoing a rapid transformation as artificial intelligence technologies become central to cancer diagnostics, personalized medicine, and clinical decision-making.
The U.S. AI in oncology market continues to lead, valued at USD 1.38 billion in 2024 and projected to reach USD 8.26 billion by 2032, expanding at a CAGR of 25.17%. The rise in cancer prevalence, demand for real-time diagnostic insights, and integration of AI algorithms into imaging and genomic analysis platforms are key forces driving this growth.
Get a Sample Report of AI in Oncology Market Forecast: https://www.snsinsider.com/sample-request/7194
AI-enabled oncology solutions are increasingly being deployed to accelerate drug discovery, predict treatment outcomes, and detect cancer at earlier stages. Health systems worldwide are investing in AI-based tools that enhance diagnostic precision while reducing workload and costs.
Segmentation Insights:
By Component Type
In 2024, hardware is the leading category under the AI in oncology market, which was valued at 40.2% AI in oncology market share of revenue. This leadership is driven by the growing need for high-performance computing infrastructure globally. Software solutions is expected to be the fastest-growing segment in the market, as AI-based solutions are increasingly being integrated with diagnostic platforms, workflow assistance, and decision support platforms.
By Cancer Type
In 2024, breast cancer was the largest segment of the AI in oncology market, accounting for an AI in oncology market share of 21.3% due to the increasing number of mammography and digital breast tomosynthesis for early detection and classification. Prostate cancer segment is expected to be the fastest growing, driven by the increase in AI-assisted MRI interpretation and image-guided biopsy optimization.
By Application
In 2024, the most widespread application of AI in oncology was diagnostics, which occupied 37.3% of the total AI in oncology market due to the prevalence of diagnostics is supported by the ever-increasing demand for accurate, point-of-care (POC), and high-throughput cancer detection devices. The increase in use of AI tools to tailor drug dosing, predict toxicity, and assess responses to treatment means that the chemotherapy category is projected to grow the fastest.
By End-Use
Hospitals dominated the AI in oncology market with the largest share of 49.3% during the forecast period due to the wide usage of AI-based imaging solutions, diagnostic tools, and treatment planning systems in hospitals. The highest growth rate is projected in the surgical centers and medical institutes with the rising demand for AI-powered robotic surgery systems, AI-enhanced intraoperative imaging systems, and AI-based precision oncology platforms.
Purchase Single User PDF of AI in Oncology Market Report: https://www.snsinsider.com/checkout/7194
Major Players Analysis Listed in the AI in Oncology Market Report are
- Azra AI
- IBM
- Siemens Healthcare GmbH
- Intel Corporation
- GE HealthCare
- NVIDIA Corporation
- Digital Diagnostics Inc.
- ConcertAI
- Median Technologies
- PathAI
- MVision AI and Others
Regional Insights:
The North American region led the AI in oncology market in 2024 due to the presence of leading market players specifically working in the field of AI-based oncology, and early adoption of AI-based technologies along with precision medicines in the region.
Asia Pacific is the fastest-growing market in the AI in oncology market globally, primarily due to the increasing cancer prevalence, burgeoning need for improved analytical solutions in diagnostics, digital healthcare infrastructure, and government efforts.
Recent Developments:
- In April 2025, Azra AI announced an expansion of its end-to-end oncology platform, enhancing automation and care coordination features to further streamline cancer diagnosis and patient management.
- In January 2025, Pathos AI emerged with USD 100 million in Series A funding to launch an AI platform focused on transforming oncology drug discovery and clinical trial optimization.
Exclusive Sections of the Report (The USPs):
- CANCER INCIDENCE & PREVALENCE ANALYTICS – helps you understand cancer burden by type across key regions in 2024, highlighting target areas where AI-driven oncology solutions are most impactful.
- AI ADOPTION & CLINICAL TRIAL LANDSCAPE – helps you track regional adoption of AI tools in oncology and ongoing clinical trials, revealing maturity levels and innovation hotspots from 2021–2024.
- END-USER USAGE INSIGHTS – helps you identify usage patterns across hospitals, research institutes, and pharma companies, offering visibility into how AI software is integrated into oncology workflows.
- INVESTMENT & FUNDING TRENDS – helps you analyze venture capital flow and institutional funding for oncology AI innovations globally and regionally, indicating future growth and partnership opportunities.
- HEALTHCARE IT INFRASTRUCTURE & REGULATORY METRICS – helps you assess regional IT readiness and regulatory support for AI in oncology, guiding strategic deployment and compliance planning.
- COST REDUCTION & EFFICIENCY BENCHMARKS – helps you evaluate how AI integration is lowering operational costs, improving diagnostic accuracy, and accelerating treatment decision-making in oncology care.
Do you have any specific queries or need any customized research on AI in Oncology Market? Submit your inquiry here: https://www.snsinsider.com/enquiry/7194
AI in Oncology Market Report Scope
| Report Attributes | Details |
| Market Size in 2024 | USD 4.22 Billion |
| Market Size by 2032 | USD 27.17 Billion |
| CAGR | CAGR of 26.23% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Key Segments | • By Component Type (Software Solutions, Hardware, and Services)
• By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, and Others) • By Application (Diagnostics (Pathology, Cancer Radiology), Radiation therapy (Radiotherapy), Research & Development (Drug design, development process, etc.), Chemotherapy, and Immunotherapy) • By End Use (Hospitals, Surgical Centers & Medical Institutes, and Others) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Access Complete Report Details of AI in Oncology Market Analysis & Outlook: https://www.snsinsider.com/reports/ai-in-oncology-market-7194
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.